EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR ‐mutated NSCLC with high thrombospondin‐1 expression

Naomi Onda iD, Shinji Nakamichi iD, Mariko Hirao, Kuniko Matsuda, Masaru Matsumoto iD, Akihiko Miyanaga iD, Rintaro Noro iD, Akihiko Gemma, Masahiro Seike

Cancer Science · 2024

DOI: 10.1111/cas.16199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Naomi Onda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Thrombospondin 1, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osimertinib induces a marked response in non–small‐cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) gene mutations. However, acquired resistance to osimertinib remains an inevitable problem. In this study, we aimed to investigate osimertinib‐resistant mechanisms and evaluate the combination therapy of afatinib and chemotherapy. We established osimertinib‐resistant cell lines (PC‐9‐OR and H1975‐OR) from EGFR‐mutant lung adenocarcinoma cell lines PC‐9 and H1975 by high exposure and stepwise method. Combination therapy of afatinib plus carboplatin (CBDCA) and pemetrexed (PEM) was effective in both parental and osimertinib‐resistant cells. We found that expression of thrombospondin‐1 (TSP‐1) was upregulated in resistant cells using cDNA microarray analysis. We demonstrated that TSP‐1 increases the expression of matrix metalloproteinases through integrin signaling and promotes tumor invasion in both PC‐9‐OR and H1975‐OR, and that epithelial‐to‐mesenchymal transition (EMT) was involved in H1975‐OR. Afatinib plus CBDCA and PEM reversed TSP‐1‐induced invasion ability and EMT changes in resistant cells. In PC‐9‐OR xenograft mouse models (five female Balb/c‐Nude mice in each group), combination therapy strongly inhibited tumor growth compared with afatinib monotherapy (5 mg/kg, orally, five times per week) or CBDCA (75 mg/kg, intraperitoneally, one time per week) + PEM (100 mg/kg, intraperitoneally, one time per week) over a 28‐day period. These results suggest that the combination of afatinib plus CBDCA and PEM, which effectively suppresses TSP‐1 expression, may be a promising option in EGFR‐mutated NSCLC patients after the acquisition of osimertinib resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombospondin 1Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsAfatinibErbB ReceptorsAcrylamidesMutationAntineoplastic Combined Chemotherapy ProtocolsAniline CompoundsHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysCarboplatinFemaleEpithelial-Mesenchymal TransitionMice, NudeGene Expression Regulation, NeoplasticMice, Inbred BALB CIndolesPyrimidines

Stichwörter der Autor:innen

epidermal growth factor receptorepithelial‐to‐mesenchymal transitionmatrix metalloproteinasenon–small‐cell lung cancerthrombospondin 1

Substanzen

Thrombospondin 1AfatinibErbB ReceptorsAcrylamidesosimertinibEGFR protein, humanAniline CompoundsCarboplatinthrombospondin-1, humanIndoles

Autor:innen und Institutionen

  • Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

ORCID-Profile: Naomi Onda, Shinji Nakamichi, Masaru Matsumoto, Akihiko Miyanaga, Rintaro Noro

Förderung

  • Boehringer Ingelheim Japan

Zitieren

APA

Onda, N., Nakamichi, S., Hirao, M., Matsuda, K., Matsumoto, M., Miyanaga, A., Noro, R., Gemma, A., & Seike, M. (2024). Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR ‐mutated NSCLC with high thrombospondin‐1 expression. Cancer Science. https://doi.org/10.1111/cas.16199

Vancouver

Onda N, Nakamichi S, Hirao M, Matsuda K, Matsumoto M, Miyanaga A, et al. Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR ‐mutated NSCLC with high thrombospondin‐1 expression. Cancer Science. 2024. doi:10.1111/cas.16199

BibTeX
@article{Onda2024,
  author = {Onda, Naomi and Nakamichi, Shinji and Hirao, Mariko and Matsuda, Kuniko and Matsumoto, Masaru and Miyanaga, Akihiko and Noro, Rintaro and Gemma, Akihiko and Seike, Masahiro},
  title = {Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR ‐mutated NSCLC with high thrombospondin‐1 expression},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16199}
}
Kostenlos starten →